

DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy

Emil Mladenov, Simon Magin, Aashish Soni and George Iliakis*

Institute of Medical Radiation Biology, University of Duisburg-Essen Medical School, Essen, Germany

Edited by:

Adam Paul Dicker, Thomas Jefferson University, USA

Reviewed by:

Fatih Uckun, University of Southern California, USA

Aaron Howard Wolfson, University of Miami Miller School of Medicine, USA

*Correspondence:

George Iliakis, Institute of Medical Radiation Biology, University of Duisburg-Essen Medical School, Hufelandstr. 55, 45122 Essen, Germany.
e-mail: georg.iliakis@uk-essen.de

Radiation therapy plays an important role in the management of a wide range of cancers. Besides innovations in the physical application of radiation dose, radiation therapy is likely to benefit from novel approaches exploiting differences in radiation response between normal and tumor cells. While ionizing radiation induces a variety of DNA lesions, including base damages and single-strand breaks, the DNA double-strand break (DSB) is widely considered as the lesion responsible not only for the aimed cell killing of tumor cells, but also for the general genomic instability that leads to the development of secondary cancers among normal cells. Homologous recombination repair (HRR), non-homologous end-joining (NHEJ), and alternative NHEJ, operating as a backup, are the major pathways utilized by cells for the processing of DSBs. Therefore, their function represents a major mechanism of radiation resistance in tumor cells. HRR is also required to overcome replication stress – a potent contributor to genomic instability that fuels cancer development. HRR and alternative NHEJ show strong cell-cycle dependency and are likely to benefit from radiation therapy mediated redistribution of tumor cells throughout the cell-cycle. Moreover, the synthetic lethality phenotype documented between HRR deficiency and PARP inhibition has opened new avenues for targeted therapies. These observations make HRR a particularly intriguing target for treatments aiming to improve the efficacy of radiation therapy. Here, we briefly describe the major pathways of DSB repair and review their possible contribution to cancer cell radioresistance. Finally, we discuss promising alternatives for targeting DSB repair to improve radiation therapy and cancer treatment.

Keywords: DNA double-strand breaks, ionizing radiation, homologous recombination repair, radiosensitization, cancer

INTRODUCTION

During the past few decades extensive efforts have been made to improve cancer therapy both by establishing more successful treatment approaches, as well as by developing effective means for early diagnosis. Despite advances in many fronts, radiation remains one of the most successful treatment modalities for solid cancers that is applied to over 50% of all cancers at one stage of their management (Delaney et al., 2005; Connell and Hellman, 2009; Ahmad et al., 2012; Siegel et al., 2012).

Radiation therapy aims to cure cancer by eradicating tumor cells. The tool of radiation therapy, ionizing radiation (IR), induces a plethora of DNA lesions, including oxidative base damages, single-strand breaks (SSBs), and double-strand breaks (DSBs), which affect the DNA integrity or alter its chemical nature (Ward, 1990). Among these lesions, DSBs have been reported to trigger the most detrimental effects on genome stability, and have been identified as the main contributors to IR induced cell killing through the formation of chromosomal aberrations (Povirk, 2006; Iliakis et al., 2007).

However, while treating tumors, radiation also always reaches normal tissue risking the development of side effects and the

generation of secondary malignancies. As a result, the central challenge of radiation therapy is to maximize tumor cell killing and minimize at the same time the normal tissue side effects. Modern conformal, intensity-modulated radiation therapy approximates this goal by optimizing radiation dose deposition between tumor and the surrounding normal tissue. Further improvements are possible using biological approaches that exploit differences in radiation response between normal and tumor cells and aim at protecting normal cells while maximizing the radiation response of tumor cells. Thus, radiosensitizing agents offer a benefit when radiosensitization occurs rather specifically in cancer cells.

The observation that components of the homologous recombination repair (HRR) pathway are aberrantly expressed in many tumors (Connell et al., 2006; Klein, 2008; Miyagawa, 2008; Tennstedt et al., 2012) and the correlation between tumor radioresistance, poor prognosis, and increased HRR activity make this repair pathway an attractive target with potential for differential responses. This view is further reinforced by the highly selective cell killing exerted by PARP-inhibitors in HRR deficient cells. However, similar conclusions have been also drawn for other DSB repair pathways (see below).

In the present review, we give a brief overview of the current state of knowledge in DSB repair and outline how this information may be harnessed to improve radiation therapy.

All used abbreviations are indicated in **Table A1** in Appendix.

THE DSB REPAIR ARSENAL

Double-strand breaks are generated randomly in the genomic DNA after exposure of cells to IR, or after treatment with radiomimetic drugs, DNA replication inhibitors, or topoisomerase poisons (Povirk, 2012). DSBs also arise randomly throughout the genome from reactive oxygen species generated as byproducts of the cellular metabolism, as well as from errors during DNA replication, the improper elimination of which may contribute to cancer progression (Vilenchik and Knudson, 2003).

Notably, DSBs are also generated in a programmed manner as part of important cellular processes, such as the maturation of lymphoid cells or gametogenesis during meiosis (Keeney et al., 1997; Panizza et al., 2011; Schatz and Swanson, 2011). In both cases specific enzymes are involved in the production of DSBs that are generated under stringent control, mostly at pre-defined locations in the genome.

In cancer therapy, the lethal effects of randomly induced DSBs are exploited to eliminate actively proliferating tumor cells. However, since induction of DSBs by IR appears comparable in normal and tumor cells, specificity of IR-toxicity to cancer cells is likely to rely either on their increased proliferative activity, or on defects in the processing of DSBs. Indeed, tumor cells frequently exhibit defects in various DNA repair pathways, which generate opportunities for enhanced treatment efficacy.

Two mechanistically and genetically distinct pathways contribute to the elimination of DSBs from the genome of higher eukaryotes: non-homologous end-joining (NHEJ), which can be subdivided in DNA-PKcs dependent NHEJ (D-NHEJ) and alternative/backup NHEJ (B-NHEJ) (see below), and HRR.

DSB REPAIR BY D-NHEJ

D-NHEJ catalyzes a simple rejoining reaction between two DNA ends irrespective of their origin (Lieber, 2010) and does not require homology at the ends or elsewhere; these facts render NHEJ operational throughout the cell-cycle. Indeed, D-NHEJ is active in all phases of the cell-cycle, where it removes DSBs from the genome with similar efficiency, but possesses only limited functionality for single-ended DSBs that arise during replication (Metzger and Iliakis, 1991; Rothkamm et al., 2003; Helleday et al., 2007).

The key steps of the classical form of NHEJ are summarized in **Figure 1**. The high affinity of KU heterodimer for free DNA ends ($1-10 \times 10^{-9}$ M, depending on the DNA end-structures), makes it the ultimate initiation factor of this repair pathway (Arosio et al., 2002). Indeed, it has been shown that the two subunits of the KU heterodimer, KU70 and KU80, which form an asymmetric toroid structure, are perfectly designed to bind and thread on free DNA ends (**Figure 1**). The binding of KU to DSBs blocks nucleolytic processing of DNA ends, which is required for the initiation of other DSB repair pathways (see below). However, despite its reported lyase activity (Roberts et al., 2010; Strande et al., 2012), the essential role of KU during NHEJ is to recruit the catalytic subunit of the DNA-PKcs, which dominates and drives the repair of DSBs in cells of higher eukaryotes. Hence, this form of repair has also been termed D-NHEJ (Mladenov and Iliakis, 2011).

The binding and dimerization of DNA-PKcs immobilizes the two DNA ends and thus facilitates the rejoining reaction (Meek et al., 2004). The interactions of DNA-PKcs with KU, as well as the




FIGURE 1 | Schematic representations of DSB repair by non-homologous end-joining. The process is initiated by the binding of KU heterodimer to the DNA ends, which then recruits DNA-PKcs to form an active DNA-PK holoenzyme. DNA-PK activation helps the recruitment of multiple proteins involved in the limited DNA end-processing (Artemis, pol μ , pol λ , and TDK) required to generate ligatable DNA ends. Ligation is mediated exclusively by the LIG4/XRCC4 complex and is assisted by the ligation mediator XLF. At the end of this process the DNA integrity at the break is restored, but the DNA sequence at the junction may be altered.

binding of DNA-PKcs to the DNA result in almost 10-fold increase in DNA-PKcs kinase activity. Accumulating evidence shows that a variety of proteins specifically involved in D-NHEJ, or generally in the DNA damage response (DDR), are phosphorylation targets of DNA-PKcs. However, interference with these phosphorylations is often without effect in DSB repair, and the only modification, which severely affects the end-joining efficiency, is elimination of DNA-PKcs auto-phosphorylation (Meek et al., 2004). Depending on the nature of DNA lesions, DNA-PKcs can be phosphorylated at multiple residues, which is a prerequisite for its dissociation from the damaged sites and the recruitment of other repair factors (**Figure 1**).

Since DSBs generated by IR bear damaged nucleotides at their ends, a limited end-processing by nucleolytic enzymes or DNA polymerases (pol μ and pol λ) is required to generate ligatable ends (Weterings and Chen, 2008) (**Figure 1**). As a result, sequence changes at the junctions generated by NHEJ are possible and therefore mutations likely. Furthermore, since D-NHEJ rejoins DNA ends indiscriminately, it can lead to translocations and other chromosomal rearrangements that are hallmarks of genomic instability. It is therefore quite surprising that despite such limitations, cells of higher eukaryotes extensively utilize D-NHEJ to remove DSBs from their genome.

The final step during D-NHEJ is mediated by a highly specialized ligation complex consisting of DNA Ligase 4 (LIG4) and the X-ray cross complementing 4 (XRCC4) protein (LIG4/XRCC4) (**Figure 1**). Assisted by the auxiliary factor XLF (Cernunos), LIG4/XRCC4 mediates ligation that results in fast and efficient restoration of DNA integrity, albeit often at the cost of sequence information loss.


DSB REPAIR BY B-NHEJ

During the past decade a second pathway for rejoining of broken DNA molecules on the basis of NHEJ was discovered and is presently intensively investigated. As with D-NHEJ this repair pathway also lacks means to restore sequence information at the DSB, and as we will discuss later, it also has a higher probability to join unrelated DNA ends.

Initially, analyses of DSB repair using pulse-field gel electrophoresis (PFGE) in cells deficient in components of D-NHEJ, revealed a robust repair activity that was unrelated to HRR (see below) and reflected a different form of DNA end-joining instead (DiBiase et al., 2000; Singh et al., 2009). This alternative form of DSB repair efficiently substituted for D-NHEJ, but appeared to have backup functions, coming to the fore mainly after failure of D-NHEJ; therefore the term B-NHEJ was proposed for this repair pathway (Iliakis, 2009; Mladenov and Iliakis, 2011). Failures of D-NHEJ, which allow function of B-NHEJ, can also occur locally at a specific DSB, even in repair proficient cells, or globally in cells with mutations in genes encoding for D-NHEJ factors, or after treatment with DNA-PKcs inhibitors. Subsequent work documented the function of such alternative pathways of NHEJ in several processes involving the formation of DSBs, such as V(D)J recombination and class switch recombination (Corneo et al., 2007), and were also implicated in cancer formation (Simsek et al., 2011).

Several enzymatic activities have been implicated in this repair pathway, which is now considered to be distinct from D-NHEJ and which may even be further subdivided into sub-pathways (Wang et al., 2005; Rosidi et al., 2008; Zha et al., 2009; Lee-Theilen et al., 2011; Mladenov and Iliakis, 2011).

A major protein implicated in B-NHEJ is poly (ADP-ribose) polymerase 1 (PARP-1), which plays a main role in the repair of SSBs (see below) and which may effectively compete with KU heterodimer for DNA end-binding (Wang et al., 2006). It has been reported that PARP-1 facilitates the repair of DSBs by B-NHEJ, while another member of the PARP family, PARP-2 strongly suppresses it (Robert et al., 2009) (**Figure 2**). It has also been reported that B-NHEJ benefits from microhomology at the break



sites, which may be best found if the DNA ends become resected. Indeed, MRE11 and C-terminal binding protein 1 interacting protein (CtIP), both involved in DNA end-resection during HRR (see below), were found to facilitate B-NHEJ (Zha et al., 2009; Lee-Theilen et al., 2011) (**Figure 2**). However, it is important to point out that B-NHEJ does not exhibit a strict requirement for microhomology, therefore, this repair pathway should not be considered as a microhomology dependent (Mansour et al., 2010).

Backup NHEJ, like D-NHEJ, is active in all phases of the cell-cycle, but its activity is significantly potentiated during S and G2, probably due to the increased activity of DNA end-resection enzymes in these cell-cycle phases. Therefore, it is likely that B-NHEJ also operates as a backup to HRR in the G2 and S-phases of the cell-cycle (see below). Notably, B-NHEJ is severely compromised when D-NHEJ deficient cells enter a plateau phase of growth or are deprived of serum (Singh et al., 2011, 2012). An intriguing and still unexplained observation is that this effect is not observed in DNA-PKcs deficient cells (Singh et al., 2011).

A ligation activity finalizing B-NHEJ is DNA Ligase 3 (LIG3), a versatile ligase, which in complex with XRCC1 also participates in the repair of SSBs and DNA base damages (Wang et al., 2005; Della-Maria et al., 2011) (**Figure 2**). Assisted by its unique structural

properties, LIG3 ensures the ligation of both DNA strands during DSB repair (Ellenberger and Tomkinson, 2008). However, despite reports to the opposite (Audebert et al., 2004), the role of XRCC1 in LIG3 function during B-NHEJ remains unclear (Della-Maria et al., 2011; Boboila et al., 2012). Recent evidence also implicates DNA Ligase 1 (LIG1) in B-NHEJ (Simsek et al., 2011; Paul et al., 2013). Thus, it appears that while LIG4 is specifically dedicated to D-NHEJ, LIG1, and LIG3 can efficiently support B-NHEJ.

Furthermore, interesting regulatory proteins were implicated in B-NHEJ. The Werner syndrome helicase (WRN), together with LIG3, was found upregulated in chronic myelogenous leukemia (CML), where several D-NHEJ activities are suppressed. Under these conditions WRN and LIG3 form a stable complex, which is recruited to DSBs, thus activating the ligation process (Sallmyr et al., 2008) (Figure 2). Moreover, a form of error-prone repair, with characteristics of single-strand annealing (SSA), was described in many myeloproliferative disorders, which are characterized by the formation of oncogenic fusion tyrosine kinases, including BCR/ABL, TEL/ABL, TEL/JAK2, and TEL/PDGFR (Cramer et al., 2008). This form of repair contributes to the accumulation of intrachromosomal deletions and translocations, a hallmark of the B-NHEJ repair pathway; therefore it has been suggested that it might be a sub-pathway of alternative DSB repair mechanisms (Mladenov and Iliakis, 2011).


Another factor implicated in B-NHEJ is histone H1, which enhances the rejoining activity of LIG3 presumably by facilitating the synapsing of DNA molecules (Rosidi et al., 2008).

Backup NHEJ is much slower than D-NHEJ and is highly error-prone causing translocations and other genomic rearrangements with high probability. Moreover, a high number of B-NHEJ associated genetic rearrangements have been observed in chromosomal translocations associated with both spontaneous and therapy-related cancers (Greaves and Wiemels, 2003). Thus, B-NHEJ-derived mutations appear to be associated with cancer development and may support tumor progression – particularly when classical NHEJ or HRR are compromised (Bennardo et al., 2008). It is therefore conceivable that activation of B-NHEJ fuels the evolution of cancer, and that it might also serve as target in specialized cancer therapies.

DSB REPAIR BY HRR


The second approach to DSB repair, HRR, requires intact homologous DNA sequences to remove DSBs and to faithfully restore the DNA sequence in their vicinity (San Filippo et al., 2008). One form of HRR (described in Figures 3 and 4) utilizes the sister chromatid as a donor for homologous sequence and is therefore active only in S and G2 phases of the cell-cycle (Onn et al., 2008; San Filippo et al., 2008). In principle, HRR could also be carried out in diploid cells during the G1 phase of the cell-cycle using the homologous chromosome as template. However, the distinct compartmentalization of the nuclear domains of homologous chromosomes make required interactions unfavorable; in fact, it is thought that HRR is actively suppressed in G1 cells in an effort to prevent loss of heterozygosity (LOH) (Paques and Haber, 1999; Aylon and Kupiec, 2004).

DNA end-resection is a necessary requirement for the initiation of HRR, as a long single-stranded 3'-DNA overhang has to be



formed in order to start homology search (West, 2003). Activities implicated in diverse aspects of end-resection include the MRE11-RAD50-NBS1 (MRN complex), the CtIP, as well as Exonuclease 1 (EXO1), DNA2, and the Bloom's syndrome helicase (BLM) (see below) (Figure 3). In order to execute their function during HRR initiation, the MRN complex is quickly recruited to DSB, where it cooperates with CtIP to promote end-resection (Sartori et al., 2007; Kousholt et al., 2012; Leslie, 2013). It is thought that end-resection defines the point of no-return in the decision to process a DSB by HRR. Therefore, the formation of single-stranded DNA regions is frequently used as a surrogate for ongoing HRR. However, as noted above, it is also possible that HRR abrogation after resection will shunt DSBs to B-NHEJ (we will return to this point below).

The combined action of DNA end-resection enzymes results in the formation of single-stranded DNA, decorated by the replication protein A (RPA) (Figure 3). RPA is a heterotrimeric complex, comprising of RPA70, RPA32, and RPA14, which exhibits high affinity for binding to ssDNA regions, such as those formed during DNA replication and occasionally during repair. In the subsequent steps of HRR, RPA is replaced by RAD51 recombinase, which forms a right-handed pre-synaptic RAD51 nucleoprotein filament on the DNA (Figure 3). The replacement of RPA by RAD51



requires the activity of mediator proteins, such as Breast cancer susceptibility gene 2 (BRCA2) and a group of five RAD51 paralogs (RAD51B, RAD51C, RAD51D, XRCC2, and XRCC3), which share 20–30% sequence similarity with the RAD51 recombinase (West, 2003).

The exact function of the RAD51 paralogs remains elusive, but there is evidence that they may form distinct complexes, which facilitate the formation and stabilization of the RAD51 filament (Masson et al., 2001; Forget et al., 2004; Suwaki et al., 2011); they also exhibit some specific functions in telomere maintenance and probably during DDR (Tarsounas et al., 2004; Badie et al., 2009). The accumulation of RAD51 monomers at the damaged sites and

the formation of a RAD51 nucleoprotein filament, can be visualized by immunofluorescence microscopy as distinct sub-nuclear RAD51 foci, which are routinely utilized to investigate DSB repair by HRR (Haaf et al., 1995).

The formation of RAD51 nucleoprotein filament is regulated by specific enzymatic activities, which displace RAD51 molecules or facilitate their association. The newly characterized PARI protein together with a RECQL5 helicase may act as a negative regulator of RAD51 filament formation (Karpenshif and Bernstein, 2012) (Figure 4). Moreover, the “anti-recombinase” proteins BLM and RTEL1, could also have negative impact on the already formed RAD51 filament, thus facilitating its dissociation

when HRR is disadvantageous (Karpenshif and Bernstein, 2012) (**Figure 4**).

In the subsequent steps of HRR, the RAD51 nucleoprotein filament invades the intact double-stranded DNA molecule to search for homologous sequences and form a structure termed displacement loop (D-loop). When homology is found (synapsis) DNA synthesis will start elongating the 3'-end of the invading strand (**Figure 4**). For elongation to commence, RAD51 in the synaptic complex has to be removed from the very 3' tip of the invading strand to reveal the 3'-OH group for priming; this reaction is facilitated by RAD54 and its interacting partner RAD54B (Li and Heyer, 2009). HRR can take several different routes from this point. Frequently, elongation of the invading 3'-end can continue over a limited distance, followed by displacement of the newly synthesized stretch and re-ligation with the original DNA end resulting in the repair of the DSB (synthesis-dependent strand annealing; SDSA) (**Figure 4**). This is the most frequent event during DSB repair in cells of higher eukaryotes and is equivalent to gene conversion. Alternatively, second end-capture can occur, leading to the formation of a double Holliday junction (dHJ) (DSB repair; DSBR) (**Figure 4**). Depending on the resolution of the dHJ by specialized resolving enzymes, GEN1 and possibly MUS81/EME1, this branch of HRR will result in either crossover or non-crossover (gene conversion) outcomes (Constantinou et al., 2002; Wu and Hickson, 2003; Ip et al., 2008) (**Figure 4**).

First reported in yeast and later in higher eukaryotes, recombination events between areas of homology present in the same DNA molecule could be observed. This process is known as SSA (Ivanov et al., 1996). When this pathway is used to repair a DSB it leads to loss of the DNA segment between the regions of homology and therefore it is considered as mutagenic. The role of SSA in the repair of randomly induced DSBs, such as those generated by IR, remains uncharacterized and is likely to be small. However, there is evidence for a correlation between increased formation of chromosomal aberrations and SSA in cells of myeloproliferative disorders expressing oncogenic fusion tyrosine kinases (Cramer et al., 2008).

Finally, in yeast another mode of HRR – termed break induced replication (BIR) – has been described, that steps into action when one sided DSBs are formed. It is characterized by the initiation of replication through the formation of a replication fork that replicates the entire chromosome past the DSB (Fan et al., 2004). As a result of this peculiarity, BIR can cause extensive LOH (Llorente et al., 2008). However in mammalian cells the action of BIR remains to be demonstrated.

REGULATION OF HRR – WAYS TO MODULATE THE REPAIR PATHWAY CHOICE

Some competition between the DSB repair processes described above is often considered likely (Sonoda et al., 2006; Shrivastav et al., 2008). Although the basis of DSB repair pathway choice in cells of higher eukaryotes remains largely elusive, it is clear that one important determinant is the position of the cell in the cell-cycle – particularly for HRR (see above). In addition to its requirement for a sister chromatid, HRR is also regulated throughout the cell-cycle in at least two ways: (1) Cell-cycle dependent regulation of the expression levels of proteins involved in HRR and (2) through

cyclin dependent kinase (CDK)-dependent phosphorylation of some of its components.

Expression levels of RAD51, Breast cancer susceptibility gene 1 (BRCA1), BRCA2, BLM, and CtIP are all regulated throughout the cell-cycle (Flygare et al., 1996; Yamamoto et al., 1996; Wang et al., 1997; Dutertre et al., 2000; Yu and Chen, 2004; Shrivastav et al., 2008). The respective transcripts and/or proteins are present at low levels in G1 and are hardly detectable or completely absent in non-dividing, G0 cells. Their expression begins with the start of DNA replication and increases further with the progression of cells through S.


One example of CDK-mediated regulation of HRR is the phosphorylation of Ser-3291 of BRCA2, which counteracts the interaction with RAD51 and thereby negatively regulates HRR activity (Esashi et al., 2005) (**Figure 5**). Another regulatory CDK-mediated phosphorylation occurs at Ser-432 of NBS1 (**Figure 5**), which is believed to act as a primary sensor of DSBs. Phosphorylation of Ser-432 on NBS1 stimulates the conversion of DSBs into substrates for HRR in a MRN-dependent manner (Falck et al., 2012).

Although MRE11, another member of the MRN complex, can act as a nuclease and is involved in facilitating resection of ends at sites of DSBs, the formation of extensive ssDNA regions seems to be carried out by other nucleases like EXO1 and possibly DNA2 (Bolderson et al., 2010; Eid et al., 2010; Grabarz et al., 2012; Tomimatsu et al., 2012) (**Figure 3**) and is facilitated by CtIP and RECQ family members like BLM (Gravel et al., 2008; Mimitou and Symington, 2008; Huertas, 2010).

CtIP not only interacts with the MRN complex, but also with BRCA1 and this interaction is promoted by CDK dependent phosphorylation of CtIP on Ser-327 in S/G2, providing yet another example for cell-cycle regulation of HRR (Yu and Chen, 2004) (**Figure 5**). CtIP is also polyubiquitinated in a BRCA1 dependent manner, without being targeted for proteasomal degradation (Yu et al., 2006). However, these are not the only cell-cycle dependent, regulatory modifications CtIP is subjected to. Phosphorylation of CtIP on Thr-847 by CDKs is required for efficient end-resection, and non-phosphorylatable mutants of this site are defective in end-resection, while phospho-mimicking mutants show resection even in the absence of CDK activity (Huertas and Jackson, 2009).

Moreover, it has been previously reported that CtIP is phosphorylated at Ser-664/745 by the Ataxia telangiectasia mutated (ATM) protein kinase, which plays an important role during DSB repair by homologous recombination (Li et al., 2000). Recently, this observation was extended using Ser-664/745-Ala (phosphomutant) and Ser-664/745-Glu (phospho-mimicking) forms of CtIP fused to GFP; it was thus found that ATM is directly engaged in DNA end-resection by activating CtIP via phosphorylation at Ser-664/745 (Shibata et al., 2011).

Although various models emerge as to how HRR is regulated throughout the cell-cycle, the question of choice for a particular repair pathway for each DSB remains poorly understood. There is however, evidence for crosstalk between HRR and NHEJ and it has been reported that DNA-PKcs, ATM, and ATM and Rad3 related (ATR) (in a CHK1/2 independent manner) collaborate to dissociate a p53/RPA-complex by phosphorylating both of its components (Serrano et al., 2012) (**Figure 5**). Notably, abrogation of these phosphorylations impairs HRR.



A large number of proteins are subjected to post-translational modifications (PTMs) that are elicited by DNA damage or replication stress. We will focus on a small selection of PTMs of proteins that either play a central role in HRR, or exert regulatory functions at key HRR steps.

As mentioned above, CtIP is critical in the regulation of end-resection and is itself post-translationally modified in several ways. Also EXO1, one of the major nucleases implicated in DNA end-resection, has been shown to be phosphorylated at multiple sites. Phosphorylation of EXO1 at Ser-714 by ATM, for example, is required for the recruitment of RAD51 to sites of DSBs (Matsuoka et al., 2007; Bolderson et al., 2010) (Figure 5). Interestingly, this phosphorylation seems to attenuate the nuclease activity of EXO1, suggesting that it might protect from over-resection.

Another level of regulation of end-resection involves p53 binding protein 1 (53BP1) and BRCA1. Interestingly loss of 53BP1 on top of BRCA1 deficiency restores a resistant phenotype in these radiosensitive cells (“synthetic viability”) (Bouwman et al., 2010; Bunting et al., 2010). This has led to a model in which 53BP1 inhibits initiation of DNA end-resection and thus favors the repair by NHEJ. This inhibition is regulated in a negative way by BRCA1 and thus, loss of BRCA1 results in persistent inhibition of end-resection, which can be abolished by removal of 53BP1 (Aly and Ganesan, 2011). A number of very recent publications have now implicated the protein RIF1 as the major downstream effector of the end-protecting function of 53BP1 (Chapman et al., 2013; Di Virgilio et al., 2013; Escribano-Diaz et al., 2013; Zimmermann et al., 2013). One of these studies also found a cell-cycle dependent inhibitory function of 53BP1 on BRCA1 accumulation at DSB in

G1 (Escribano-Diaz et al., 2013), which could account for HRR suppression in G1.

The ssDNA generated during resection is immediately covered with RPA. The middle subunit of RPA (RPA32/RPA2) is a target for multiple PTMs, which may have important roles in the subsequent steps of HRR (Figure 5). It has been shown that hyperphosphorylation of RPA32 is required for RAD51 recruitment in response to replication stress induced by hydroxyurea (HU); however such dependencies were not identified after IR or endonuclease induced DSBs (Shi et al., 2010).

Phosphorylations are not the only form of PTMs induced by DNA damage. Besides the well-known waves of ubiquitylation mediated by the E3-ubiquitin-ligases RNF8 and RNF168, modification with small ubiquitin like modifiers (SUMO) also occurs in response to DNA breaks. RPA70 is sumoylated on at least two sites *in vivo*, but this modification is suppressed by a constitutive interaction of the SUMO-specific protease SENP6 (Dou et al., 2010). In response to replication associated DSBs this interaction is abrogated, which allows sumoylation of RPA70 that promotes HRR (Dou et al., 2010). It has also been reported, that the ubiquitin-ligase activity of BRCA1 depends on its sumoylation (Morris et al., 2009). For the BLM helicase multiple sites of sumoylation have been documented as well and shown to influence its nuclear localization and possibly to act as switches shifting BLM-activity between pro- and anti-recombinogenic functions (Eladad et al., 2005; Ouyang et al., 2009).

Upon formation of a RAD51 coated ssDNA the stability of this nucleoprotein filament is critical for the execution of HRR. In mammalian cells helicases like BLM or RECQ5 have been shown to dismantle RAD51 nucleoprotein filaments (Bugreev et al., 2007; Hu et al., 2007) (Figure 4). Very recently it was shown that the helicase domain containing protein PARI suppresses unscheduled and inappropriate HRR at replication forks in human and chicken cells (Moldovan et al., 2012) (Figure 4). This function is mediated by its interaction with PCNA and might be analogous to the function of Srs2 in yeast.

RAD51 itself can also be post-translationally modified in several ways. Following replication stress, RAD51 is phosphorylated in a CHK1 dependent manner on Thr-309 (Sorensen et al., 2005), and also by the c-ABL tyrosine kinase on Tyr-315, which stabilize association of RAD51 with chromatin (Shimizu et al., 2009) (Figure 5). Two additional phosphorylations of RAD51 that occur in a cell-cycle and DNA damage dependent manner have been recently reported: RAD51 is phosphorylated on Ser-14 by PLK1 which licenses phosphorylation of Thr-13 by CK2 (Yata et al., 2012) (Figure 5). Phosphorylation of Thr-13 leads to direct binding of RAD51 to NBS1, which facilitates its recruitment to sites of DNA damage (Yata et al., 2012).

It is evident from the outline above that the cell-cycle regulation of HRR has different levels and is likely to be complex. Identification of these modifications and characterization of their functional significance is likely to have important implications to our understanding of repair pathway choice.

REGULATION OF HRR BY TYROSINE KINASE SIGNALING

Besides the above described intrinsic cell-cycle dependent regulatory processes, there is evidence for additional regulatory levels

modulating repair of DSBs. An important example is the BCR-ABL fusion tyrosine kinase, a hallmark of CML (Skorski, 2012). The non-mutated c-ABL protein is activated by DNA-PKcs and ATM in response to genotoxic stress (Kharbanda et al., 1995; Baskaran et al., 1997). There are reports suggesting that the constitutively active fusion protein contributes to drug resistance, stimulates HRR, and promotes ectopic recombination events, through either up-regulation of RAD51 levels and/or direct phosphorylation of RAD51 on Tyr-315 (Slupianek et al., 2001, 2002, 2011; Skorski, 2002; Nowicki et al., 2004) (Figure 5).

Up-regulation of mutagenic SSA (see above) by BCR-ABL has also been reported, and BCR-ABL stimulated expression of CtIP and increased DNA end-resection have been suggested as a mechanism (Cramer et al., 2008; Fernandes et al., 2009; Salles et al., 2011). Notably, HRR is negatively regulated by the normal form of c-ABL in irradiated cells by a phosphorylation of RAD51 on Tyr-54 (Yuan et al., 1998) (Figure 5). Another study shows that Rad51 is phosphorylated on both Tyr-315 and Tyr-54 by c-ABL and that these phosphorylations are sequential, with the phosphorylation of Tyr-315 stimulating phosphorylation of Tyr-54 (Popova et al., 2009). Thus, c-ABL may fine-tune recombination repair by balancing activating and inhibitory RAD51 phosphorylations, whereas the constitutively active BCR-ABL protein may cause its hyperactivation with mutagenic consequences. Interestingly, it has been reported, that in ABL-positive CML cells, there is also a shift toward more mutagenic NHEJ repair processes. Sallmyr et al. found LIG4 and Artemis to be down-regulated in these cells, while LIG3 was upregulated. Since in these cells error-prone NHEJ was observed, the authors concluded that the activity of B-NHEJ was enhanced (Brady et al., 2003; Sallmyr et al., 2008).

While the regulatory influence of the ABL kinase on DSB repair has been mainly linked to DDR responses mediated by DNA-PKcs and ATM, there are also examples of modulation of DSB repair through receptor tyrosine kinases activated by their natural extracellular ligands. Over the last 15 years, evidence has accumulated that overexpression and/or mutation of the EGF receptor (EGFR) is associated with resistance to chemo- and radiotherapy (Chen and Nirodi, 2007; Dittmann et al., 2010; Toulany and Rodemann, 2010).

While EGFR is known to exert a cytoprotective action through the activation of cell survival and proliferation pathways, a large body of evidence also implicates EGFR signaling in DSB repair. In glioblastomas, brain tumors characterized by resistance to chemo- and radiotherapy, the EGFR gene is amplified in 50% of the cases and a truncated variant – EGFRvIII – is frequently over expressed. Mukherjee et al. (2009) showed that the expression of this constitutively active EGFR variant confers radioresistance through activation of PI3K-AKT signaling that enhances DSB repair.

In another study the authors showed by scoring γ -H2AX foci that activation of EGFR signaling by its natural ligand EGF enhanced the overall capacity of cells to repair DSBs (Kriegs et al., 2010). Conversely inhibition of EGFR signaling by Erlotinib or Cetuximab reduced DSB repair. The authors found that EGFR activation increased NHEJ, possibly through enhanced MAPK signaling. Another study from the same group showed a positive effect of EGFR activation on HRR (Myllynen et al., 2011). This observation is in agreement with work reported by Golding et al.

(2009) who demonstrated up-regulation of both NHEJ and HRR by EGFRvIII with assays utilizing appropriate, chromosomally integrated reporter constructs.

Several reports also indicate an interference of Imatinib, Erlotinib, and other tyrosine kinase inhibitors (Chinnaiyan et al., 2005; Li et al., 2008; Choudhury et al., 2009; Zhao et al., 2011; Medova et al., 2012; Qiao et al., 2013) with HRR. These results confirm the potential impact of these signaling proteins on DSB repair and highlight their importance as targets for cancer therapy.

DSB REPAIR DEFICIENCY AND CARCINOGENESIS

The observation that in many cancer cells the DDR is impaired emphasizes the connection between DSB repair defects and carcinogenesis and generates opportunities for cancer treatment. Indeed, various forms of cancer present with mutations or show alterations in the expression of genes encoding proteins involved in DNA metabolism (Connell et al., 2006; Klein, 2008; Miyagawa, 2008; Tennstedt et al., 2012). Furthermore, among cancers, the activities of certain repair proteins fluctuate, from complete suppression to strong up-regulation, which necessarily modulates their response to DNA damaging agents. These observations suggest that optimization of cancer therapy will benefit from in-depth analysis of the status of the DDR apparatus in each individual tumor and an adaptation of the treatment strategy to this information.

More specifically, a strong correlation between increased genomic instability, DNA repair defects, and cancer predisposition has been documented in cells isolated from individuals carrying germ line mutations in *BRCA1* or *BRCA2* genes (O'Donovan and Livingston, 2010; Roy et al., 2012). The *BRCA1* and *BRCA2* mutations increase the susceptibility to breast or ovarian cancer, and it has been estimated that the probability of developing these forms of cancer is between 30 and 80% in individuals carrying hetero- or homozygous mutations in these genes (Brody and Biesecker, 1998).

The breast cancer associated gene 1 (*BRCA1*) was identified in 1990 (Walsh and King, 2007) and was cloned a few years later (Miki et al., 1994). Biochemical and structural analyses of human *BRCA1* protein revealed an N-terminal RING domain possessing E3-ubiquitin-ligase activity and a C-terminal BRCT domain, interacting with proteins phosphorylated on serine within the S-X-X-F motif. *BRCA1* consists of 1863 amino acids and plays an important role in maintaining genome integrity through its functions in DNA repair (Rajagopalan et al., 2010; Roy et al., 2012). To become a functional E3-ubiquitin-ligase, the RING domain of *BRCA1* acts in concert with *BRCA1*-associated RING domain 1 protein (*BARD1*), and this complex is involved in the ubiquitylation of CtIP (see above). Despite controversial studies, assigning critical functions for *BRCA1* in NHEJ and nucleotide excision repair (NER), mounting evidence implicates *BRCA1* as a key regulator of HRR (Jasin, 2002; Roy et al., 2012).

The direct recruitment of *BRCA1* to DSBs is mediated by its interaction with Abraxas-RAP80 macro-complex, which binds to ubiquitylated proteins, particularly histones (Wang et al., 2007). Once recruited to DSBs, the main regulatory function of *BRCA1* is to conscript and activate the end-resection promoting factor CtIP (Yun and Hiom, 2009). However, *BRCA1* is not only implicated in

HRR by its role in end-resection, but also due to its indirect interaction with *BRCA2*, which is mediated by the *PALB2* protein (Zhang et al., 2009). Indeed, heterozygous mutations of the latter protein are also associated with predisposition to breast and pancreatic cancers (Popova et al., 2009). This interaction directly connects *BRCA1* to HRR and indeed, deficiency of *BRCA1* is accompanied by abrogated formation of DSB-induced RAD51 foci and severely reduced levels of HRR.

A variety of studies with cultured cell lines has revealed that *BRCA1* deficiency correlates with increased radiosensitivity to killing, which derives from the associated HRR defects (Speit and Trenz, 2004). These observations are further supported by results showing decreased survival of irradiated *BRCA1*^{-/-} mouse embryonic fibroblasts exposed to IR and emphasize the central role of HRR in the maintenance of genomic integrity. Notably, more recent results suggest that inactivation of *BRCA1* ubiquitin-ligase activity up-regulates protein complexes involved in DNA end-resection, causing elevated but aberrant HRR that undermines genomic instability (Drost et al., 2011; Dever et al., 2012). Along these lines, C61G mutation in the *BRCA1* gene is associated with complete loss of *BRCA1* E3-ubiquitin-ligase function, and disruption of the *BRCA1/BARD1* complex, which results in increased formation of RAD51 foci, and abnormal rate of HRR (Drost et al., 2011). Such results explain the observation that many sporadic *BRCA1* deficient tumors develop radioresistance – possibly through enhanced aberrant HRR that triggers the function of the highly mutagenic B-NHEJ repair pathway (see above).

Although the frequency of developing breast and ovarian cancer in individuals harboring mutations in the *BRCA2* gene is lower than in individuals harboring *BRCA1* mutations, *BRCA2*-deficient patients have a 20-fold increased risk of developing prostate cancer and about 10-fold increased risk to pancreatic and other form of tumors like medulloblastomas and gliomas (Roy et al., 2012). This suggests that despite common functions in DNA repair, *BRCA1* and *BRCA2* also have specific functions, which explains the distinct behavior described above.

Breast cancer susceptibility gene 2 (*BRCA2*) is a 3418 amino acids protein, harboring a specific domain consisting of about 30 degenerative BRC repeats that are responsible for the controlled formation of RAD51 and DMC1 nucleoprotein filaments during HRR and meiosis, respectively (Thorslund and West, 2007; Roy et al., 2012). The BRC repeats exhibit subtle sequence variations allowing differential binding of RAD51 and mediating the controlled displacement of RPA from ssDNA regions and the nucleation of RAD51 monomers, which culminates with the formation of a nucleoprotein filament (West, 2003) (Figure 2). The importance of BRC repeats in *BRCA2* function has been demonstrated in patients with point mutations in this domain, which develop breast and ovarian cancer with much higher frequency than patients with mutations in other regions of the gene.

Available biochemical data suggest that the main function of *BRCA2* in DSB repair is to keep RAD51 in monomeric state and to deliver RAD51 monomers to the resected DNA ends. As mentioned above, the potential of *BRCA2* to bind RAD51 is tightly regulated by CDK1 phosphorylation at Ser-3291, in the C-terminal TR2 motif (Esashi et al., 2005, 2007), whose abrogation results

in intolerable HRR and increased genomic instability, but which might be exploited to enhance the killing potential of IR.

However, it is relevant to point out that all these well described functions in DSB repair, are not sufficient to explain initiation and progression of cancer in individuals with mutation in *BRCA* genes. Certainly, it might be speculated that *BRCA1* and *BRCA2* are important for tumor suppression by virtue of their function in HRR. Alternatively, it might be speculated that both proteins suppress error-prone DSB repair pathways. A strong candidate for such effects is B-NHEJ, whose involvement in DSB repair may increase when HRR is abrogated. Moreover, reports that B-NHEJ benefits from the presence of microhomology and the fact that end-resection activities like CtIP and MRN complex facilitate B-NHEJ (Xie et al., 2009; Lee-Theilen et al., 2011), support the idea that B-NHEJ may exploit failures in HRR (see above). This is especially true when limited resection of DNA ends is already accomplished, as this will prevent the recruitment of key factors of classical NHEJ. Another possibility, explaining the tumor susceptibility of *BRCA*-deficient patients is that the common genetic alterations (e.g., *BRCA1* or *BRCA2* mutations) are regularly associated with loss of wild-type p53 (Ramus et al., 1999), ATM (Tommiska et al., 2008), or *CHK2* (Cao et al., 2006). These additional alterations may permit cells to bypass checkpoint controls and evade apoptosis, thereby commencing tumorigenesis.

Multiple studies link mutations in other DSB repair genes with genomic instability and cancer predisposition. Prominent among them, AT, AT like disorder (ATLD), and the NBS display mutations in genes involved in the repair of DSBs by HRR. Thus, in AT patients, ATM activity is abrogated and these individuals primarily develop lymphoid malignancies. The ATLD and NBS syndromes are associated with mutations in *MRE11* and *NBS1* genes, which together with *RAD50* form the MRN complex, involved in initiation of DNA end-resection for HRR (Stracker and Petrini, 2011).

HRR DEFICIENCY AS AN OPPORTUNITY IN CANCER THERAPY: THE CONCEPT OF SYNTHETIC LETHALITY

DNA damaging agents used in cancer treatment induce a spectrum of lesions in the DNA. These lesions are recognized by a variety of cellular lesion-specific DNA repair pathways that operate to remove them from the affected DNA molecules. It is commonly accepted that DSBs are substrates for NHEJ (Lieber, 2010) and HRR (San Filippo et al., 2008). The function of these DNA repair pathways rescues malignant cells from death following exposure to radiation or chemotherapeutic drugs and compromise thus cancer treatment. It follows that inhibition of these repair processes, preferentially in malignant cells, should enhance the efficacy of cancer therapies based on killing cells by the induction of DSBs. Indeed, evidence accumulates that success in cancer treatment often results from DNA repair deficiencies in the cancer cells. Also, it has been observed that when DSB repair deficient tumors develop resistance to radiation or to DSB inducing drugs, they do so by improving their DSB repair potential (Zwet et al., 2002).

Our present understanding of DSB induction and repair allows us to postulate that combination of cytotoxic agents acting by inducing DSBs with inhibitors of DSB repair will enhance tumor cell killing – if this inhibition, or alternatively the induction of

DSBs, could be somehow preferentially targeted to tumor cells. Similar arguments can be developed for other forms of DNA damage and other pathways of DNA repair.

A number of inhibitors of DNA repair have been evaluated, or are undergoing clinical trials, as potential anti-cancer chemicals. Inhibitors of PARP-1 are of particular interest in treating hereditary breast cancers occurring in patients who are carriers of *BRCA1* or *BRCA2* mutations (Bryant et al., 2005; Farmer et al., 2005). As mentioned above, *BRCA2* has been established as an integral component of the HRR machinery, regulating the assembly of *RAD51* filaments and facilitating strand exchange (Thorslund and West, 2007; Carreira and Kowalczykowski, 2009). Also HRR is impaired in *BRCA1* deficient cells.

Poly (ADP-ribose) polymerase 1 is known to be involved in SSB repair, BER, and NER in association with *XRCC1*, *LIG3*, *PNK*, *PCNA*, and *FEN1* (Frouin et al., 2003; Okano et al., 2003). PARP-1 is also involved in DSB repair (Küpper et al., 1995; Tatsumi-Miyajima et al., 1999; Rudat et al., 2001), as well as in the alternative/backup pathways of NHEJ (Wang et al., 2006; Iliakis, 2009). The combination of PARP-inhibitors with *BRCA* deficiency provides a sound paradigm for the power of synthetic lethality as a strategy for improving cancer treatment. Synthetic lethality emerges when the combination of non-lethal mutations in two or more genes operating in different metabolic pathways, or the chemical inhibition of their products, causes cell death.

As expected from the basic premise of synthetic lethality, PARP-1 is also effective in tumors with HRR defects deriving from genes other than *BRCA* – sometimes referred to as “BRCAness” (de Gonzalez et al., 2011). Thus, deficiency in *RAD51*, *RAD54*, *DSS1*, *RPA1*, *NBS1*, *ATR*, *ATM*, *CHK1*, *CHK2*, *FANCD2*, or *FANCC* genes was found to be associated with synthetic lethality to PARP inhibition (McCabe et al., 2006). These results confirm that the critical role of *BRCA1* and *BRCA2* in HRR is the underlying reason for the hyper-sensitivity to PARP-inhibitors of *BRCA*-deficient tumors. Collectively, these results indicate that the approach of synthetic lethality with PARP-1 inhibitors may prove useful for the treatment of a wide range of tumors bearing HRR deficiencies, or displaying properties of “BRCAness.”

An interesting synthetic lethal interaction has been established between *RAD52* and *BRCA2*. Loss of *RAD52* function is synthetically lethal with *BRCA2* deficiency in human cancer cell lines (Feng et al., 2011; Lok et al., 2012). This suggests that *BRCA2* and *RAD52* provide alternative pathways for *RAD51* mediated HRR in mammalian cells. *RAD52* also exerts other synthetic lethal phenotypes: in chicken DT40 cells its inactivation is lethal when it occurs together with inactivation of *XRCC3* (Fujimori et al., 2001). On the other hand, the viability of *BRCA2*-deficient DT40 cells is not compromised by deletion of *RAD52*; rather, an epistatic relationship between *BRCA2* and *RAD52* is suggested in these cells (Qing et al., 2011). Combined defects in the *BRCA2* ortholog *Brh2* and *Rad52* generate a very subtle synthetic lethal phenotype in *U. maydis* (Kojic et al., 2008). These differences between human and other species point to the care required in the generalization of synthetic lethal interactions among species and restrict significantly the spectrum of model organisms that can be used in their study.

Poly (ADP-ribose) polymerase 1 inhibition shows synergistic interactions in combination with *CHK1* inhibition and is thought

to be mediated by the induction of apoptosis. CHK1 induced phosphorylation of ERK1/2 and H2AX is abolished after PARP-1 inhibition (Mitchell et al., 2010). However, the suppression of HRR by CHK1 inhibition makes this kinase an excellent target for synthetic lethality with PARP-1 inhibition also according to the rational framework outlined above.

In agreement with this expectation, Hattori et al. established a BRCA2 synthetic lethal RNAi screen, which identified CHK1 as a potential therapeutic target. Unexpectedly, though, CHK1 inhibitors failed to suppress the growth of BRCA2-deficient cells in the context of KRAS activation and TP53 inactivation found in pancreatic cancers (Hattori et al., 2011). This study extends the above outlined precautions and emphasizes that synthetic lethal interactions identified by *in vitro* screens may fail to show effectiveness in the genetic context of specific cancer forms. Evidently, the identification of synthetic lethal interactions and their exploitation in cancer therapy requires extreme care, appropriate experimentation, and model systems closely resembling the tumor whose cure is envisioned.

IMPACT ON RADIATION THERAPY OF ABNORMAL EXPRESSION OF RAD51

Cancer cell lines show fluctuations in the level of expression of genes involved in cell-cycle control and DDR. The variable expression of genes implicated in HRR, particularly overexpression of *RAD51*, is seen in many tumors and is linked to increased radio- or chemo-resistance. Moreover, a high level of *RAD51* expression is observed in a variety of tumor cell lines (Richardson, 2005) and is associated with a poor outcome in the therapy of lung cancer (Qiao et al., 2005).

In addition, mammalian cells with elevated *RAD51* level show genomic instability (Richardson et al., 2004), increased spontaneous recombination, and resistance to IR or to chemotherapeutic agents (Vispe et al., 1998). All these findings associate increased level of *RAD51* with genomic instability and cancer development. This is surprising considering that the functions of *RAD51* in HRR would predict the opposite, i.e., improved repair capacity. Indeed, it has been shown that many leukemia-related disorders, ovarian and breast carcinomas, as well as colon and rectal adenocarcinomas show, when irradiated, increased formation of *RAD51* foci, which correlates with radioresistance (Raderschall et al., 2002; Klein, 2008). Moreover, the HRR deficiency of cells lacking *RAD51* paralogs or *BRCA1* can be completely or partially rescued by *RAD51* overexpression (Schild and Wiese, 2010). Another report shows that mRNA and protein levels of *RAD51*, *XRCC3*, *RAD52*, and *RAD54* genes are two to fivefold elevated in malignant prostate cancer cell lines (Fan et al., 2004).

Interestingly, the high *RAD51* levels in these tumors are not mediated by *RAD51* gene amplification; rather overexpression is driven by aberrant oncogene related transcriptional activation. This suggests problems with the regulation of DNA metabolism in cancer cells. Major culprit for such behavior is the mutation in the tumor suppressor gene *p53*, which was found to negatively regulate *RAD51* expression (Arias-Lopez et al., 2006; Hannay et al., 2007). As *p53* is the most frequently mutated gene in human cancers (Hansen et al., 2003), a *RAD51*-related radio- and chemo-resistance are likely consequences.

However, fluctuations in *RAD51* level in tumor cells cannot be completely explained by mutations in *p53* gene. There are examples of *RAD51* over expression in a functional *p53* background, suggesting a multilevel control of *RAD51* expression. In these cases high *RAD51* level is associated with *p53*-dependent expression of *p21^{Waf-1}*, which affects the rate of *BRCA1* transcription and the activation of cell-cycle checkpoint response (Walsh et al., 2011). Therefore, a strong G2 cell-cycle arrest is detected in *RAD51*-overexpressing cells, which occurs through *p21* mediated *CDK1* inactivation (Raderschall et al., 2002).

It is relevant to speculate how increased *RAD51* protein levels confer radioresistance in tumor cells, especially when additional mutations are generated in DNA repair genes that should make them radiosensitive.

There are reports suggesting a positive correlation between HRR and high levels of *RAD51*. Thus, *p53* deficient Chinese hamster ovary cells show elevated HRR when transfected with a vector mediating overexpression of the *RAD51* gene (Bertrand et al., 2003). Furthermore, using an I-Sce-I-based reporter system in mouse ES cells (Habrand and Le Pechoux, 2004), it was found that *RAD51* over expression increases HRR. Yet, in the latter case increased HRR was associated with aberrant recombination events including crossovers, chromosome translocations, as well as multiple chromosome rearrangements and aneuploidy, suggesting frequent abrogation of HRR and possibly the engagement of B-NHEJ.

Thus, for successful HRR, *RAD51* levels must be precisely regulated; otherwise chromosomal instability may ensue. The correspondence between *RAD51* over expression, increased HRR, and resistance to chemotherapeutic drugs suggest the possibility for developing treatment strategies based on *RAD51* down regulation – by specific inhibitors or RNAi.

RADIOSENSITIZATION BY CHEMOTHERAPEUTIC AGENTS THROUGH INHIBITION OF HRR

As outlined above, intact or hyperactive HRR often correlates with resistance to therapy, while defects in HRR, when not associated with sensitivity to treatment, offer opportunities for synthetic lethality. It is timely, therefore, to explore means to inhibit HRR in cells proficient in this repair pathway. The potential benefit of this approach is reinforced by the observation that several compounds with antitumor activity and wide application in the clinic also inhibit HRR, and thus generate opportunities for synergistic interactions.

Radiosensitizing effects, in addition to their cytotoxic action, have been demonstrated for many chemotherapeutic drugs. Although the radiosensitizing effects of some of those drugs, e.g., 5-fluorouracil (5-FU), have been known for decades, the underlying mechanisms remain largely unclear. However, the number of radiosensitizers that are found to inhibit HRR is growing. These include nucleoside and base analogs like gemcitabine (Wachters et al., 2003), TAS-106 (Meike et al., 2011), and gimeracil (Takagi et al., 2010) as well as other antimetabolites like pentoxifylline and caffeine (Asaad et al., 2000; Böhm, 2006). Furthermore the ATR inhibitor VE-821 (Prevo et al., 2012) and the CHK1/2 inhibitor AZD7762 (Morgan et al., 2010) have been reported to inhibit HRR.

There is also a growing list of inhibitory substances and therapeutics, which are less directly linked to DNA metabolism and damage response, but which are suggested to radiosensitize tumor cells by inhibiting HRR. These include the tyrosine kinase inhibitors imatinib and erlotinib (Chinnaiyan et al., 2005; Li et al., 2008; Choudhury et al., 2009), the HDAC inhibitor PCI-24781 (Adimoolam et al., 2007), the proteasome inhibitor MG132 (Murakawa et al., 2007), and 17-AAG, an inhibitor of HSP90 (Noguchi et al., 2006). Moreover, mild hyperthermia was found to inhibit HRR and to sensitize cells to PARP-inhibitors (Krawczyk et al., 2011; Bergs et al., 2013). In addition specific inhibitors of HRR are now being identified in specialized screens, like BO2, which inhibits the RAD51 activity in strand exchange (Huang et al., 2012) and RI-1, a specific inhibitor of RAD51 that covalently binds to RAD51 and suppresses RAD51 nucleoprotein filament formation (Budke et al., 2012).

Finally, it should be pointed out that IR, but also many widely used chemotherapeutic compounds induce large amounts of base damage, or generate replication errors that require mismatch repair for correction. As a result, it is possible to significantly improve cancer treatment by developing strategies for the

simultaneous inhibition during treatment of some of these repair pathways, or by exploiting genetic defects in cancer cells in these repair pathways (Kinsella, 2009).

CONCLUSION

It is evident from the above outline that a wealth of information and a variety of approaches are evolving that promise to improve the outcome of radiation therapy beyond the precise and more specific targeting of the radiation dose to the tumor. These approaches are aided and accelerated by rapid advances in synthetic chemistry and in protein structure information. As a result, they are likely to mature quickly and to open a new era of opportunities in radiation therapy. Radiation oncologists are likely to benefit significantly from these developments, if they closely follow them and quickly adapt them to the requirements of treatment of human tumors by IR.

ACKNOWLEDGMENTS

Work supported by Grants from the “Bundesministerium für Bildung und Forschung” (BMBF: 02NUK005C and 03NUK001B) and the “Bundesministerium für Wirtschaft und Technologie” (BMW: ESA-AO-08-IBER, 50WB1229).

REFERENCES

- Adimoolam, S., Sirisawad, M., Chen, J., Thiemann, P., Ford, J. M., and Buggy, J. J. (2007). HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. *Proc. Natl. Acad. Sci. U.S.A.* 104, 19482–19487.
- Ahmad, S. S., Duke, S., Jena, R., Williams, M. V., and Burnet, N. G. (2012). Advances in radiotherapy. *BMJ* 345, 33–38.
- Aly, A., and Ganesan, S. (2011). BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. *J. Mol. Cell Biol.* 3, 66–74.
- Arias-Lopez, C., Lazaro-Trueba, I., Kerr, P., Lord, C. J., Dexter, T., Iravani, M., et al. (2006). p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene. *EMBO Rep.* 7, 219–224.
- Arosio, D., Cui, S., Ortega, C., Chovanec, M., Di Marco, S., Baldini, G., et al. (2002). Studies on the mode of Ku interaction with DNA. *J. Biol. Chem.* 277, 9741–9748.
- Asaad, N. A., Zeng, Z.-C., Guan, J., Thacker, J., and Iliakis, G. (2000). Homologous recombination as a potential target for caffeine radiosensitization in mammalian cells: reduced caffeine radiosensitization in XRCC2 and XRCC3 mutants. *Oncogene* 19, 5788–5800.
- Audebert, M., Salles, B., and Calso, P. (2004). Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. *J. Biol. Chem.* 279, 55117–55126.
- Aylon, Y., and Kupiec, M. (2004). New insights into the mechanism of homologous recombination in yeast. *Mutat. Res.* 566, 231–248.
- Badie, S., Liao, C., Thanasoula, M., Barber, P., Hill, M. A., and Tarsounas, M. (2009). RAD51C facilitates checkpoint signaling by promoting CHK2 phosphorylation. *J. Cell Biol.* 185, 587–600.
- Baskaran, R., Wood, L. D., Whitaker, L. L., Canman, C. E., Morgan, S. E., Xu, Y., et al. (1997). Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. *Nature* 387, 516–519.
- Bennardo, N., Cheng, A., Huang, N., and Stark, J. M. (2008). Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair. *PLoS Genet.* 4:e1000110. doi:10.1371/journal.pgen.1000110
- Bergs, J. W., Krawczyk, P. M., Borovski, T., Ten Cate, R., Rodermond, H. M., Stap, J., et al. (2013). Inhibition of homologous recombination by hyperthermia shunts early double strand break repair to non-homologous end-joining. *DNA Repair (Amst.)* 12, 38–45.
- Bertrand, P., Lambert, S., Joubert, C., and Lopez, B. S. (2003). Overexpression of mammalian Rad51 does not stimulate tumorigenesis while a dominant-negative Rad51 affects centrosome fragmentation, ploidy and stimulates tumorigenesis, in p53-defective CHO cells. *Oncogene* 22, 7587–7592.
- Boboila, C., Oksenyh, V., Gostissa, M., Wang, J. H., Zha, S., Zhang, Y., et al. (2012). Robust chromosomal DNA repair via alternative end-joining in the absence of X-ray repair cross-complementing protein 1 (XRCC1). *Proc. Natl. Acad. Sci. U.S.A.* 109, 2473–2478.
- Böhm, L. (2006). Inhibition of homologous recombination repair with Pen-toxifylline targets G2 cells generated by radiotherapy and induces major enhancements of the toxicity of cisplatin and melphalan given after irradiation. *Radiat. Oncol.* 1, 12.
- Bolderson, E., Tomimatsu, N., Richard, D. J., Boucher, D., Kumar, R., Pandita, T. K., et al. (2010). Phosphorylation of Exo1 modulates homologous recombination repair of DNA double-strand breaks. *Nucleic Acids Res.* 38, 1821–1831.
- Bouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., Van Der Gulden, H., et al. (2010). 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. *Nat. Struct. Mol. Biol.* 17, 688–695.
- Brady, N., Gaymes, T. J., Cheung, M., Mufti, G. J., and Rassool, F. V. (2003). Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key nonhomologous end-joining proteins. *Cancer Res.* 63, 1798–1805.
- Brody, L. C., and Biesecker, B. B. (1998). Breast cancer susceptibility genes. BRCA1 and BRCA2. *Medicine (Baltimore)* 77, 208–226.
- Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., et al. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature* 434, 913–917.
- Budke, B., Logan, H. L., Kalin, J. H., Zeli-vianskaia, A. S., Cameron McGuire, W., Miller, L. L., et al. (2012). RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. *Nucleic Acids Res.* 40, 7347–7357.
- Bugreev, D. V., Yu, X., Egelman, E. H., and Mazin, A. V. (2007). Novel pro- and anti-recombination activities of the Bloom’s syndrome helicase. *Genes Dev.* 21, 3085–3094.
- Bunting, S. F., Callén, E., Wong, N., Chen, H.-T., Polato, F., Gunn, A., et al. (2010). 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. *Cell* 141, 243–254.
- Cao, L., Kim, S., Xiao, C., Wang, R.-H., Li, W. M., Xu, L. X., et al. (2006). ATM-Chk2-p53 activation prevents tumorigenesis at an expense of organ homeostasis upon Brca1 deficiency. *EMBO J.* 25, 2167–2177.
- Carreira, A., and Kowalczykowski, S. C. (2009). BRCA2 shining light on the regulation of DNA-binding selectivity by RAD51. *Cell Cycle* 8, 3445–3447.

- Chapman, J. R., Barral, P., Vannier, J. B., Borel, V., Steger, M., Tomas-Loba, A., et al. (2013). RIF1 is essential for 53BP1-dependent nonhomologous end joining and suppression of DNA double-strand break resection. *Mol. Cell* 5, 858–871.
- Chen, D. J., and Nirodi, C. S. (2007). The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. *Clin. Cancer Res.* 13, 6555–6560.
- Chinnaiyan, P., Huang, S., Vallabhaneni, G., Armstrong, E., Varambally, S., Tomlins, S. A., et al. (2005). Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). *Cancer Res.* 65, 3328–3335.
- Choudhury, A., Zhao, H., Jalali, F., Al Rashid, S., Ran, J., Supiot, S., et al. (2009). Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. *Mol. Cancer Ther.* 8, 203–213.
- Connell, P. P., and Hellman, S. (2009). Advances in radiotherapy and implications for the next century: a historical perspective. *Cancer Res.* 69, 383–392.
- Connell, P. P., Jayathilaka, K., Haraf, D. J., Weichselbaum, R. R., Vokes, E. E., and Lingen, M. W. (2006). Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. *Int. J. Oncol.* 28, 1113–1119.
- Constantinou, A., Chen, X.-B., McGowan, C. H., and West, S. C. (2002). Holliday junction resolution in human cells: two junction endonucleases with distinct substrate specificities. *EMBO J.* 21, 5577–5585.
- Corneo, B., Wendland, R. L., Deriano, L., Cui, X., Klein, I. A., Wong, S.-Y., et al. (2007). Rag mutations reveal robust alternative end joining. *Nature* 449, 483–486.
- Cramer, K., Nieborowska-Skorska, M., Koptyra, M., Slupianek, A., Penserga, E. T., Eaves, C. J., et al. (2008). BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. *Cancer Res.* 68, 6884–6888.
- de Gonzalez, A., Curtis, R. E., Kry, S. F., Gilbert, E., Lamart, S., Berg, C. D., et al. (2011). Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. *Lancet Oncol.* 12, 353–360.
- Delaney, G., Jacob, S., Featherstone, C., and Barton, M. (2005). The role of radiotherapy in cancer treatment. *Cancer* 104, 1129–1137.
- Della-Maria, J., Zhou, Y., Tsai, M.-S., Kuhnlein, J., Carney, J. P., Paull, T. T., et al. (2011). Human Mre11/Human Rad50/Nbs1 and DNA ligase III α /XRCC1 protein complexes act together in an alternative nonhomologous end joining pathway. *J. Biol. Chem.* 286, 33845–33853.
- Dever, S. M., White, E. R., Hartman, M. C. T., and Valerie, K. (2012). BRCA1-directed, enhanced and aberrant homologous recombination: mechanism and potential treatment strategies. *Cell Cycle* 11, 687–694.
- Di Virgilio, M., Callen, E., Yamane, A., Zhang, W., Jankovic, M., Gitlin, A. D., et al. (2013). Rif1 prevents resection of DNA breaks and promotes immunoglobulin class switching. *Science* 339, 711–715.
- DiBiase, S. J., Zeng, Z.-C., Chen, R., Hyslop, T., Curran, W. J. Jr., and Iliakis, G. (2000). DNA-dependent protein kinase stimulates an independently active, nonhomologous, end-joining apparatus. *Cancer Res.* 60, 1245–1253.
- Dittmann, K., Mayer, C., and Rodehmann, H. (2010). Nuclear EGFR as novel therapeutic target. *Strahlenther. Onkol.* 186, 1–6.
- Dou, H., Huang, C., Singh, M., Carpenter, P. B., and Yeh, E. T. H. (2010). Regulation of DNA repair through DeSUMOylation and SUMOylation of replication protein A complex. *Mol. Cell* 39, 333–345.
- Drost, R., Bouwman, P., Rottenberg, S., Boon, U., Schut, E., Klarenbeek, S., et al. (2011). BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. *Cancer Cell* 20, 797–809.
- Dutertre, S., Ababou, M., Onclercq, R., Delic, J., Chatton, B., Jaulin, C., et al. (2000). Cell cycle regulation of the endogenous wild type Bloom's syndrome DNA helicase. *Oncogene* 19, 2731–2738.
- Eid, W., Steger, M., El-Shemerly, M., Ferretti, L. P., Pena-Diaz, J., Konig, C., et al. (2010). DNA end resection by CtIP and exonuclease 1 prevents genomic instability. *EMBO Rep.* 11, 897–984.
- Eladad, S., Ye, T.-Z., Hu, P., Leversha, M., Beresten, S., Matunis, M. J., et al. (2005). Intra-nuclear trafficking of the BLM helicase to DNA damage-induced foci is regulated by SUMO modification. *Hum. Mol. Genet.* 14, 1351–1365.
- Ellenberger, T., and Tomkinson, A. E. (2008). Eukaryotic DNA ligases: structural and functional insights. *Annu. Rev. Biochem.* 77, 313–338.
- Esashi, F., Christ, N., Gannon, J., Liu, Y., Hunt, T., Jasin, M., et al. (2005). CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. *Nature* 434, 598–604.
- Esashi, F., Galkin, V. E., Yu, X., Egelman, E. H., and West, S. C. (2007). Stabilization of RAD51 nucleoprotein filaments by the C-terminal region of BRCA2. *Nat. Struct. Mol. Biol.* 14, 468–474.
- Escribano-Diaz, C., Orthwein, A., Fradet-Turcotte, A., Xing, M., Young, J. T., Tkac, J., et al. (2013). A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. *Mol. Cell* 5, 872–883.
- Falck, J., Forment, J. V., Coates, J., Mistrik, M., Lukas, J., Bartek, J., et al. (2012). CDK targeting of NBS1 promotes DNA-end resection, replication restart and homologous recombination. *EMBO Rep.* 13, 561–568.
- Fan, R., Kumaravel, T. S., Jalali, F., Marrano, P., Squire, J. A., and Bristow, R. G. (2004). Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression. *Cancer Res.* 64, 8526–8533.
- Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature* 434, 917–921.
- Feng, Z., Scott, S. P., Bussen, W., Sharma, G. G., Guo, G., Pandita, T. K., et al. (2011). Rad52 inactivation is synthetically lethal with BRCA2 deficiency. *Proc. Natl. Acad. Sci. U.S.A.* 108, 686–691.
- Fernandes, M. S., Reddy, M. M., Gonneville, J. R., Deroo, S. C., Podar, K., Griffin, J. D., et al. (2009). BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. *Blood* 114, 1813–1819.
- Flygare, J., Benson, F., and Hellgren, D. (1996). Expression of the human RAD51 gene during the cell cycle in primary human peripheral blood lymphocytes. *Biochim. Biophys. Acta* 1312, 231–236.
- Forget, A. L., Bennett, B. T., and Knight, K. L. (2004). Xrcc3 is recruited to DNA double strand breaks early and independent of Rad51. *J. Cell. Biochem.* 93, 429–436.
- Frouin, I., Maga, G., Denegri, M., Riva, F., Savio, M., Spadari, S., et al. (2003). Human proliferating cell nuclear antigen, poly(ADP-ribose) polymerase-1, and p21^{waf1/cip1}. *J. Biol. Chem.* 278, 39265–39268.
- Fujimori, A., Tachiiri, S., Sonoda, E., Thompson, L. H., Kumar Dhar, P., Hiraoka, M., et al. (2001). Rad52 partially substitutes for the Rad51 paralog XRCC3 in maintaining chromosomal integrity in vertebrate cells. *EMBO J.* 20, 5513–5520.
- Golding, S. E., Morgan, R. N., Adams, B. R., Hawkins, A. J., Povirk, L. F., and Valerie, K. (2009). Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells. *Cancer Biol. Ther.* 8, 730–738.
- Grabarz, A., Barascu, A., Guirouilh-Barbat, J., and Lopez, B. S. (2012). Initiation of DNA double strand break repair: signaling and single-stranded resection dictate the choice between homologous recombination, non-homologous end-joining and alternative end-joining. *Am. J. Cancer Res.* 2, 249–268.
- Gravel, S., Chapman, J. R., Magill, C., and Jackson, S. P. (2008). DNA helicases Sgs1 and BLM promote DNA double-strand break resection. *Genes Dev.* 22, 2767–2772.
- Greaves, M. J., and Wiemels, J. (2003). Origins of chromosome translocations in childhood leukaemia. *Nat. Rev. Cancer* 3, 639–649.
- Haaf, T., Golub, E. I., Reggy, G., Radding, C. M., and Ward, D. C. (1995). Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA damage and its localization in synaptonemal complexes. *Proc. Natl. Acad. Sci. U.S.A.* 92, 2298–2302.
- Habrand, J. L., and Le Pechoux, C. (2004). Radiation therapy in the management of adult soft tissue sarcomas. *Ann. Oncol.* 15, iv187–iv191.
- Hannay, J. A. F., Liu, J., Zhu, Q.-S., Bolshakov, S. V., Li, L., Pisters, P. W. T., et al. (2007). Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. *Mol. Cancer Ther.* 6, 1650–1660.
- Hansen, L. T., Lundin, C., Spang-Thomsen, M., Petersen, L. N., and Helleday, T. (2003). The role of Rad51 in etoposide (V16) resistance in small cell lung cancer. *Int. J. Cancer* 105, 472–479.

- Hattori, H., Skoulidis, F., Russell, P., and Venkataraman, A. R. (2011). Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor. *Mol. Cancer Ther.* 10, 670–678.
- Helleday, T., Lo, J., Van Gent, D. C., and Engelward, B. P. (2007). DNA double-strand break repair: from mechanistic understanding to cancer treatment. *DNA Repair (Amst.)* 6, 923–935.
- Hu, Y., Raynard, S., Sehorn, M. G., Lu, X., Bussen, W., Zheng, L., et al. (2007). RECQL5/Recql5 helicase regulates homologous recombination and suppresses tumor formation via disruption of Rad51 presynaptic filaments. *Genes Dev.* 21, 3073–3084.
- Huang, F., Mazina, O. M., Zentner, I. J., Cocklin, S., and Mazin, A. V. (2012). Inhibition of homologous recombination in human cells by targeting RAD51 recombinase. *J. Med. Chem.* 55, 3011–3020.
- Huertas, P. (2010). DNA resection in eukaryotes: deciding how to fix the break. *Nat. Struct. Mol. Biol.* 17, 11–16.
- Huertas, P., and Jackson, S. P. (2009). Human CtIP mediates cell cycle control of DNA end resection and double strand break repair. *J. Biol. Chem.* 284, 9558–9565.
- Iliakis, G. (2009). Backup pathways of NHEJ in cells of higher eukaryotes: cell cycle dependence. *Radiother. Oncol.* 92, 310–315.
- Iliakis, G., Wu, W., Wang, M., Terzoudi, G. I., and Pantelias, G. E. (2007). “Backup pathways of nonhomologous end joining may have a dominant role in the formation of chromosome aberrations,” in *Chromosomal Alterations*, eds G. Obe and Vijayalaxmi (Berlin: Springer Verlag), 67–85.
- Ip, S. C. Y., Rass, U., Blanco, M. G., Flynn, H. R., Skehel, J. M., and West, S. C. (2008). Identification of Holliday junction resolvases from humans and yeast. *Nature* 456, 357–361.
- Ivanov, E. L., Sugawara, N., Fishman-Lobell, J., and Haber, J. E. (1996). Genetic requirements for the single-strand annealing pathway of double-strand break repair in *Saccharomyces cerevisiae*. *Genetics* 142, 693–704.
- Jasin, M. (2002). Homologous repair of DNA damage and tumorigenesis: the BRCA connection. *Oncogene* 21, 8981–8993.
- Karpenshif, Y., and Bernstein, K. A. (2012). From yeast to mammals: recent advances in genetic control of homologous recombination. *DNA Repair (Amst.)* 11, 781–788.
- Keeney, S., Giroux, C. N., and Kleckner, N. (1997). Meiosis-specific DNA double-strand breaks are catalyzed by Spo11, a member of a widely conserved protein family. *Cell* 88, 375–384.
- Kharbanda, S., Ren, R., Pandey, P., Shafman, T. D., Feller, S. M., Weichselbaum, R. R., et al. (1995). Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. *Nature* 376, 785–788.
- Kinsella, T. J. (2009). Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers. *Clin. Cancer Res.* 15, 1853–1859.
- Klein, H. L. (2008). The consequences of Rad51 overexpression for normal and tumor cells. *DNA Repair (Amst.)* 7, 686–693.
- Kojic, M., Mao, N., Zhou, Q., Lisby, M., and Holloman, W. K. (2008). Compensatory role for Rad52 during recombinational repair in *Ustilago maydis*. *Mol. Microbiol.* 67, 1156–1168.
- Kousholt, A. N., Fugger, K., Hoffmann, S., Larsen, B. D., Menzel, T., Sartori, A. A., et al. (2012). CtIP-dependent DNA resection is required for DNA damage checkpoint maintenance but not initiation. *J. Cell Biol.* 197, 869–876.
- Krawczyk, P. M., Eppink, B., Essers, J., Stap, J., Rodermond, H., Odijk, H., et al. (2011). Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly(ADP-ribose) polymerase-1 inhibition. *Proc. Natl. Acad. Sci. U.S.A.* 108, 9851–9856.
- Kriegs, M., Kasten-Pisula, U., Rieckmann, T., Holst, K., Saker, J., Dahm-Daphi, J., et al. (2010). The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining. *DNA Repair (Amst.)* 9, 889–897.
- Küpper, J. H., Müller, M., Jacobson, M. K., Tatsumi-Miyajima, J., Coyle, D. L., Jacobson, E. L., et al. (1995). *trans*-Dominant inhibition of poly(ADP-Ribosyl)ation sensitizes cells against γ -irradiation and N-methyl-N'-nitrosoguanidine but does not limit DNA replication of a polyomavirus replicon. *Mol. Cell Biol.* 15, 3154–3163.
- Lee-Theilen, M., Matthews, A. J., Kelly, D., Zheng, S., and Chaudhuri, J. (2011). CtIP promotes microhomology-mediated alternative end joining during class-switch recombination. *Nat. Struct. Mol. Biol.* 18, 75–79.
- Leslie, M. (2013). How to live without BRCA1. *J. Cell Biol.* 200, 127.
- Li, L., Wang, H., Yang, E. S., Arteaga, C. L., and Xia, F. (2008). Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. *Cancer Res.* 68, 9141–9146.
- Li, S., Ting, N. S. Y., Zheng, L., Chen, P.-L., Ziv, Y., Shiloh, Y., et al. (2000). Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. *Nature* 406, 210–215.
- Li, X., and Heyer, W.-D. (2009). RAD54 controls access to the invading 3'-OH end after RAD51-mediated DNA strand invasion in homologous recombination in *Saccharomyces cerevisiae*. *Nucleic Acids Res.* 37, 638–646.
- Lieber, M. R. (2010). The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. *Annu. Rev. Biochem.* 79, 1.1–1.31.
- Llorente, B., Smith, C. E., and Symington, L. S. (2008). Break-induced replication: what is it and what is it for? *Cell Cycle* 7, 859–864.
- Lok, B. H., Carley, A. C., Tchang, B., and Powell, S. N. (2012). RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination. *Oncogene*. doi:10.1038/onc.2012.391
- Mansour, W. Y., Rhein, T., and Dahm-Daphi, J. (2010). The alternative end-joining pathway for repair of DNA double-strand breaks requires PARP1 but is not dependent upon microhomologies. *Nucleic Acids Res.* 38, 6065–6077.
- Masson, J.-Y., Tarsounas, M. C., Stasiak, A. Z., Stasiak, A., Shah, R., McIlwraith, M. J., et al. (2001). Identification and purification of two distinct complexes containing the five RAD51 paralogs. *Genes Dev.* 15, 3296–3307.
- Matsuoka, S., Ballif, B. A., Smogorzewska, A., McDonald III, E. R., Hurov, K. E., Luo, J., et al. (2007). ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. *Science* 316, 1160–1166.
- McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Bialkowska, A., Swift, S., et al. (2006). Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-Ribose) polymerase inhibition. *Cancer Res.* 66, 8109–8115.
- Medova, M., Aebersold, D. M., and Zimmer, Y. (2012). MET inhibition in tumor cells by PHA665752 impairs homologous recombination repair of DNA double strand breaks. *Int. J. Cancer* 130, 728–734.
- Meek, K., Gupta, S., Ramsden, D. A., and Lees-Miller, S. P. (2004). The DNA-dependent protein kinase: the director at the end. *Immunol. Rev.* 200, 132–141.
- Meike, S., Yamamori, T., Yasui, H., Eitaki, M., Matsuda, A., Morimatsu, M., et al. (2011). A nucleoside anticancer drug, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (TAS106), sensitizes cells to radiation by suppressing BRCA2 expression. *Mol. Cancer* 10, 92.
- Metzger, L., and Iliakis, G. (1991). Kinetics of DNA double strand breaks throughout the cell cycle as assayed by pulsed field gel electrophoresis in CHO cells. *Int. J. Radiat. Biol.* 59, 1325–1339.
- Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., et al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science* 266, 66–71.
- Mimitou, E. P., and Symington, L. S. (2008). Sae2, Exo1 and Sgs1 collaborate in DNA double-strand break processing. *Nature* 455, 770–774.
- Mitchell, J. B., Choudhuri, R., Fabre, K., Sowers, A. L., Citrin, D., Zabludoff, S. D., et al. (2010). In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. *Clin. Cancer Res.* 16, 2076–2084.
- Miyagawa, K. (2008). Clinical relevance of the homologous recombination machinery in cancer therapy. *Cancer Sci.* 99, 187–194.
- Mladenov, E., and Iliakis, G. (2011). Induction and repair of DNA double strand breaks: the increasing spectrum of non-homologous end joining pathways. *Mutat. Res.* 711, 61–72.
- Moldovan, G.-L., Dejsuphong, D., Petalcorin, M. I., Hofmann, K., Takeda, S., Boulton, S. J., et al. (2012). Inhibition of homologous recombination by the PCNA-interacting protein PARI. *Mol. Cell* 45, 75–86.
- Morgan, M. A., Parsels, L. A., Zhao, L., Parsels, J. D., Davis, M. A., Hassan, M. C., et al. (2010). Mechanism

- of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. *Cancer Res.* 70, 4972–4981.
- Morris, J. R., Boutell, C., Keppler, M., Densham, R., Weekes, D., Alamshah, A., et al. (2009). The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. *Nature* 462, 886–890.
- Mukherjee, B., McEllin, B., Camacho, C. V., Tomimatsu, N., Sirasana-gandala, S., Nannepaga, S., et al. (2009). EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. *Cancer Res.* 69, 4252–4259.
- Murakawa, Y., Sonoda, E., Barber, L. J., Zeng, W., Yokomori, K., Kimura, H., et al. (2007). Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells. *Cancer Res.* 67, 8536–8543.
- Myllynen, L., Rieckmann, T., Dahm-Daphi, J., Kasten-Pisula, U., Petersen, C., Dikomey, E., et al. (2011). In tumor cells regulation of DNA double strand break repair through EGF receptor involves both NHEJ and HR and is independent of p53 and K-Ras status. *Radiother. Oncol.* 101, 147–151.
- Noguchi, M., Yu, D., Hirayama, R., Ninomiya, Y., Sekine, E., Kubota, N., et al. (2006). Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin. *Biochem. Biophys. Res. Commun.* 351, 658–663.
- Nowicki, M. O., Falinski, R., Kopytyra, M., Slupianek, A., Stoklosa, T., Gloc, E., et al. (2004). BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. *Blood* 104, 3746–3753.
- O'Donovan, P. J., and Livingston, D. M. (2010). BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. *Carcinogenesis* 31, 961–967.
- Okano, S., Lan, L., Caldecott, K. W., Mori, T., and Yasui, A. (2003). Spatial and temporal cellular responses to single-strand breaks in human cells. *Mol. Cell. Biol.* 23, 3974–3981.
- Onn, I., Heidinger-Pauli, J. M., Guacci, V., Unal, E., and Koshland, D. E. (2008). Sister chromatid cohesion: a simple concept with a complex reality. *Annu. Rev. Cell Dev. Biol.* 24, 105–129.
- Ouyang, K. J., Woo, L. L., Zhu, J., Huo, D., Matunis, M. J., and Ellis, N. A. (2009). SUMO modification regulates BLM and RAD51 interaction at damaged replication forks. *PLoS Biol.* 7:e1000252. doi:10.1371/journal.pbio.1000252
- Panizza, S., Mendoza, M. A., Berlinger, M., Huang, L., Nicolas, A., Shirahige, K., et al. (2011). Spo11-accessory proteins link double-strand break sites to the chromosome axis in early meiotic recombination. *Cell* 146, 372–383.
- Paques, F., and Haber, J. E. (1999). Multiple pathways of recombination induced by double-strand breaks in *Saccharomyces cerevisiae*. *Microbiol. Mol. Biol. Rev.* 63, 349–404.
- Paul, K., Wang, M., Mladenov, E., Bencsik-Theilen, A. A., Bednar, T., Wu, W., et al. (2013). DNA ligases I and III cooperate in alternative non-homologous end-joining in vertebrates. *PLoS ONE* 8:e59505. doi:10.1371/journal.pone.0059505
- Popova, M., Shimizu, H., Yamamoto, K.-I., Lebecqec, M., Takahashi, M., and Fleury, F. (2009). Detection of c-Abl kinase-promoted phosphorylation of Rad51 by specific antibodies reveals that Y54 phosphorylation is dependent on that of Y315. *FEBS Lett.* 583, 1867–1872.
- Povirk, L. F. (2006). Biochemical mechanisms of chromosomal translocations resulting from DNA double-strand breaks. *DNA Repair (Amst.)* 5, 1199–1212.
- Povirk, L. F. (2012). Processing of damaged DNA ends for double-strand break repair in mammalian cells. *ISRN Mol. Biol.* 2012. Article ID 345805.
- Prevo, R., Fokas, E., Reaper, P. M., Charlton, P. A., Pollard, J. R., McKenna, W. G., et al. (2012). The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. *Cancer Biol. Ther.* 13, 1072–1081.
- Qiao, B., Kerr, M., Groselj, B., Teo, M. T., Knowles, M. A., Bristow, R. G., et al. (2013). Imatinib radiosensitizes bladder cancer by targeting homologous recombination. *Cancer Res.* 73, 1611–1620.
- Qiao, G. B., Wu, Y. L., Yang, X. N., Zhong, W. Z., Xie, D., Guan, X. Y., et al. (2005). High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. *Br. J. Cancer* 93, 137–143.
- Qing, Y., Yamazoe, M., Hirota, K., Dejsuphong, D., Sakai, W., Yamamoto, K. N., et al. (2011). The epistatic relationship between BRCA2 and the other RAD51 mediators in homologous recombination. *PLoS Genet.* 7:e1002148. doi:10.1371/journal.pgen.1002148
- Raderschall, E., Stout, K., Freier, S., Suckow, V., Schweiger, S., and Haaf, T. (2002). Elevated levels of Rad51 recombination protein in tumor cells. *Cancer Res.* 62, 219–225.
- Rajagopalan, S., Andreeva, A., Rutherford, T. J., and Fersht, A. R. (2010). Mapping the physical and functional interactions between the tumor suppressors p53 and BRCA2. *Proc. Natl. Acad. Sci. U.S.A.* 107, 8587–8592.
- Ramus, S. J., Bobrow, L. G., Pharoah, P. D., Finnigan, D. S., Fishman, A., Altaras, M., et al. (1999). Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours. *Genes Chromosomes Cancer* 25, 91–96.
- Richardson, C. (2005). RAD51, genomic stability, and tumorigenesis. *Cancer Lett.* 218, 127–139.
- Richardson, C., Horikoshi, N., and Pandita, T. K. (2004). The role of the DNA double-strand break response network in meiosis. *DNA Repair (Amst.)* 3, 1149–1164.
- Robert, I., Dantzer, F., and Reina-San-Martin, B. (2009). Parp1 facilitates alternative NHEJ, whereas Parp2 suppresses IgH/c-myc translocations during immunoglobulin class switch recombination. *J. Exp. Med.* 206, 1047–1056.
- Roberts, S. A., Strande, N., Burkhalter, M. D., Strom, C., Havener, J. M., Hasty, P., et al. (2010). Ku is a 5'-drp/AP lyase that excises nucleotide damage near broken ends. *Nature* 464, 1214–1217.
- Rosidi, B., Wang, M., Wu, W., Sharma, A., Wang, H., and Iliakis, G. (2008). Histone H1 functions as a stimulatory factor in backup pathways of NHEJ. *Nucleic Acids Res.* 36, 1610–1623.
- Rothkamm, K., Krüger, I., Thompson, L. H., and Löbrich, M. (2003). Pathways of DNA double-strand break repair during the mammalian cell cycle. *Mol. Cell. Biol.* 23, 5706–5715.
- Roy, R., Chun, J., and Powell, S. N. (2012). BRCA1 and BRCA2: different roles in a common pathway of genome protection. *Nat. Rev. Cancer* 12, 68–78.
- Rudat, V., Bachmann, N., Küpper, J.-H., and Weber, K.-J. (2001). Overexpression of the DNA-binding domain of poly(ADP-ribose) polymerase inhibits rejoining of ionizing radiation-induced DNA double-strand breaks. *Int. J. Radiat. Biol.* 77, 303–307.
- Salles, D., Mencialha, A. L., Ireno, I. C., Wiesmuller, L., and Abdelhay, E. (2011). BCR-ABL stimulates mutagenic homologous DNA double-strand break repair via the DNA-end-processing factor CtIP. *Carcinogenesis* 32, 27–34.
- Sallmyr, A., Tomkinson, A. E., and Rassool, F. V. (2008). Up-regulation of WRN and DNA ligase III α in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks. *Blood* 112, 1413–1423.
- San Filippo, J., Sung, P., and Klein, H. (2008). Mechanism of eukaryotic homologous recombination. *Annu. Rev. Biochem.* 77, 229–257.
- Sartori, A. A., Lukas, C., Coates, J., Mistrik, M., Fu, S., Bartek, J., et al. (2007). Human CtIP promotes DNA end resection. *Nature* 450, 509–514.
- Schatz, D. G., and Swanson, P. C. (2011). V(D)J recombination: mechanisms of initiation. *Annu. Rev. Genet.* 45, 167–202.
- Schild, D., and Wiese, C. (2010). Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instability. *Nucleic Acids Res.* 38, 1061–1070.
- Serrano, M. A., Li, Z., Dangeti, M., Musich, P. R., Patrick, S., Roginskaya, M., et al. (2012). DNA-PK, ATM and ATR collaboratively regulate p53-RPA interaction to facilitate homologous recombination DNA repair. *Oncogene*. doi:10.1038/onc.2012.257
- Shi, W., Feng, Z., Zhang, J., Gonzalez-Suarez, I., Vanderwaal, R. P., Wu, X., et al. (2010). The role of RPA2 phosphorylation in homologous recombination in response to replication arrest. *Carcinogenesis* 31, 994–1002.
- Shibata, A., Conrad, S., Birraux, J., Geuting, V., Barton, O., Ismail, A., et al. (2011). Factors determining DNA double-strand break repair pathway choice in G2 phase. *EMBO J.* 30, 1079–1092.
- Shimizu, H., Popova, M., Fleury, F., Kobayashi, M., Hayashi, N., Sakane, I., et al. (2009). c-ABL tyrosine kinase stabilizes RAD51 chromatin association. *Biochem. Biophys. Res. Commun.* 382, 286–291.
- Shrivastav, M., De Haro, L. P., and Nickoloff, J. A. (2008). Regulation of DNA double-strand break

- repair pathway choice. *Cell Res.* 18, 134–147.
- Siegel, R., Desantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., et al. (2012). Cancer treatment and survivorship statistics, 2012. *CA Cancer J. Clin.* 62, 220–241.
- Simsek, D., Brunet, E., Wong, S. Y.-W., Katyal, S., Gao, Y., Mckinnon, P. J., et al. (2011). DNA ligase III promotes alternative nonhomologous end-joining during chromosomal translocation formation. *PLoS Genet.* 7:e1002080. doi:10.1371/journal.pgen.1002080
- Singh, S. K., Bednar, T., Zhang, L., Wu, W., Mladenov, E., and Iliakis, G. (2012). Inhibition of B-NHEJ in plateau-phase cells is not a direct consequence of suppressed growth factor signaling. *Int. J. Radiat. Oncol. Biol. Phys.* 84, e237–e243.
- Singh, S. K., Wu, W., Wu, W., Wang, M., and Iliakis, G. (2009). Extensive repair of DNA double-strand breaks in cells deficient in the DNA-PK dependent pathway of NHEJ after exclusion of heat-labile sites. *Radiat. Res.* 172, 152–164.
- Singh, S. K., Wu, W., Zhang, L., Klammer, H., Wang, M., and Iliakis, G. (2011). Widespread dependence of backup NHEJ on growth state: ramifications for the use of DNA-PK inhibitors. *Int. J. Radiat. Oncol. Biol. Phys.* 79, 540–548.
- Skorski, T. (2002). BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. *Oncogene* 21, 8591–8604.
- Skorski, T. (2012). Genetic mechanisms of chronic myeloid leukemia blastic transformation. *Curr. Hematol. Malig. Rep.* 7, 87–93.
- Slupianek, A., Dasgupta, Y., Ren, S.-Y., Gurdek, E., Donlin, M., Nieborowska-Skorska, M., et al. (2011). Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia. *Blood* 118, 1062–1068.
- Slupianek, A., Hoser, G., Majsterek, I., Bronisz, A., Malecki, M., Blasiak, J., et al. (2002). Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. *Mol. Cell Biol.* 22, 4189–4201.
- Slupianek, A., Schmutte, C., Tomblin, G., Nieborowska-Skorska, M., Hoser, G., Nowicki, M. O., et al. (2001). BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. *Mol. Cell* 8, 795–806.
- Sonoda, E., Hohegger, H., Saberi, A., Taniguchi, Y., and Takeda, S. (2006). Differential usage of non-homologous end-joining and homologous recombination in double strand break repair. *DNA Repair (Amst.)* 5, 1021–1029.
- Sorensen, C. S., Hansen, L. T., Dziegielewska, J., Syljuasen, R. G., Lundin, C., Bartek, J., et al. (2005). The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. *Nat. Cell Biol.* 7, 195–201.
- Speit, G., and Trenz, K. (2004). Chromosomal mutagen sensitivity associated with mutations in BRCA genes. *Cytogenet. Genome Res.* 104, 325–332.
- Stracker, T. H., and Petrini, J. H. J. (2011). The MRE11 complex: starting from the ends. *Nat. Rev. Mol. Cell Biol.* 12, 90–103.
- Strande, N., Roberts, S. A., Oh, S., Hendrickson, E. A., and Ramsden, D. A. (2012). Specificity of the dRP/AP lyase of Ku promotes nonhomologous end joining (NHEJ) fidelity at damaged ends. *J. Biol. Chem.* 287, 13686–13693.
- Suwaki, N., Klare, K., and Tarsounas, M. (2011). RAD51 paralogs: roles in DNA damage signalling, recombinational repair and tumorigenesis. *Semin. Cell Dev. Biol.* 22, 898–905.
- Takagi, M., Sakata, K.-I., Someya, M., Tauchi, H., Iijima, K., Matsumoto, Y., et al. (2010). Gimeracil sensitizes cells to radiation via inhibition of homologous recombination. *Radiother. Oncol.* 96, 259–266.
- Tarsounas, M., Munoz, P., Claas, A., Smiraldi, P. G., Pittman, D. L., Blasco, M. A., et al. (2004). Telomere maintenance requires the RAD51D recombination/repair protein. *Cell* 117, 337–347.
- Tatsumi-Miyajima, J., Küpper, J.-H., Takebe, H., and Bürkle, A. (1999). Trans-dominant inhibition of poly (ADP-ribosyl)ation potentiates alkylation-induced shuttle-vector mutagenesis in Chinese hamster cells. *Mol. Cell. Biochem.* 193, 31–35.
- Tennstedt, P., Fresow, R., Simon, R., Marx, A., Terracciano, L., Petersen, C., et al. (2012). RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma. *Int. J. Cancer* 132, 2118–2126.
- Thorslund, T., and West, S. C. (2007). BRCA2: a universal recombinase regulator. *Oncogene* 26, 7720–7730.
- Tomimatsu, N., Mukherjee, B., Deland, K., Kurimasa, A., Bolderson, E., Khanna, K. K., et al. (2012). Exo1 plays a major role in DNA end resection in humans and influences double-strand break repair and damage signaling decisions. *DNA Repair (Amst.)* 11, 441–448.
- Tommiska, J., Bartkova, J., Heinonen, M., Hautala, L., Kilpivaara, O., Eerola, H., et al. (2008). The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER//PR//ERBB2-triple-negative breast cancer. *Oncogene* 27, 2501–2506.
- Toulany, M., and Rodemann, H. P. (2010). Membrane receptor signaling and control of DNA repair after exposure to ionizing radiation. *Nuklearmedizin* 49, S26–S30.
- Vilenchik, M. M., and Knudson, A. G. (2003). Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer. *Proc. Natl. Acad. Sci. U.S.A.* 100, 12871–12876.
- Vispe, S., Cazaux, C., Lesca, C., and Defais, M. (1998). Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. *Nucleic Acids Res.* 26, 2859–2864.
- Wachters, F. M., Van Putten, J. W. G., Maring, J. G., Zdzienicka, M. Z., Groen, H. J. M., and Kampinga, H. H. (2003). Selective targeting of homologous DNA recombination repair by gemcitabine. *Int. J. Radiat. Oncol. Biol. Phys.* 57, 553–562.
- Walsh, T., Casadei, S., Lee, M. K., Penning, C. C., Nord, A. S., Thornton, A. M., et al. (2011). Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. *Proc. Natl. Acad. Sci. U.S.A.* 108, 18032–18037.
- Walsh, T., and King, M.-C. (2007). Ten genes for inherited breast cancer. *Cancer Cell* 11, 103–105.
- Wang, B., Matsuoka, S., Ballif, B. A., Zhang, D., Smogorzewska, A., Gygi, S. P., et al. (2007). Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. *Science* 316, 1194–1198.
- Wang, H., Rosidi, B., Perrault, R., Wang, M., Zhang, L., Windhofer, F., et al. (2005). DNA ligase III as a candidate component of backup pathways of nonhomologous end joining. *Cancer Res.* 65, 4020–4030.
- Wang, M., Wu, W., Wu, W., Rosidi, B., Zhang, L., Wang, H., et al. (2006). PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. *Nucleic Acids Res.* 34, 6170–6182.
- Wang, S. C., Lin, S. H., Su, L. K., and Hung, M. C. (1997). Changes in BRCA2 expression during progression of the cell cycle. *Biochem. Biophys. Res. Commun.* 234, 247–251.
- Ward, J. F. (1990). The yield of DNA double-strand breaks produced intracellularly by ionizing radiation: a review. *Int. J. Radiat. Biol.* 57, 1141–1150.
- West, S. C. (2003). Molecular views of recombination proteins and their control. *Nat. Rev. Mol. Cell Biol.* 4, 1–11.
- Weterings, E., and Chen, D. J. (2008). The endless tale of non-homologous end-joining. *Cell Res.* 18, 114–124.
- Wu, L., and Hickson, I. D. (2003). The Bloom's syndrome helicase suppresses crossing over during homologous recombination. *Nature* 426, 870–874.
- Xie, A., Kwok, A., and Scully, R. (2009). Role of mammalian Mre11 in classical and alternative nonhomologous end joining. *Nat. Struct. Mol. Biol.* 16, 814–818.
- Yamamoto, A., Taki, T., Yagi, H., Habu, T., Yoshida, K., Yoshimura, Y., et al. (1996). Cell cycle-dependent expression of the mouse Rad51 gene in proliferating cells. *Mol. Gen. Genet.* 251, 1–12.
- Yata, K., Lloyd, J., Maslen, S., Bleuyard, J.-Y., Skehel, M., Smerdon, S. J., et al. (2012). Plk1 and CK2 act in concert to regulate Rad51 during DNA double strand break repair. *Mol. Cell* 45, 371–383.
- Yu, X., and Chen, J. (2004). DNA damage-induced cell cycle checkpoint control requires CtIP, a phosphorylation-dependent binding partner of BRCA1 C-terminal domains. *Mol. Cell Biol.* 24, 9478–9486.
- Yu, X., Fu, S., Lai, M., Baer, R., and Chen, J. (2006). BRCA1 ubiquitinates its phosphorylation-dependent binding partner CtIP. *Genes Dev.* 20, 1721–1726.
- Yuan, Z.-M., Huang, Y., Ishiko, T., Nakada, S., Utsugisawa, T., Kharbanda, S., et al. (1998). Regulation of Rad51 function by c-Abl in response to DNA damage. *J. Biol. Chem.* 273, 3799–3802.
- Yun, M. H., and Hiom, K. (2009). CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle. *Nature* 459, 460–463.
- Zha, S., Boboila, C., and Alt, F. W. (2009). Mre11: roles in DNA

- repair beyond homologous recombination. *Nat. Struct. Mol. Biol.* 16, 798–800.
- Zhang, F., Fan, Q., Ren, K., and Andreassen, P. R. (2009). PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. *Mol. Cancer Res.* 7, 1110–1118.
- Zhao, H., Luoto, K. R., Meng, A. X., and Bristow, R. G. (2011). The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination. *Radiother. Oncol.* 101, 59–65.
- Zimmermann, M., Lottersberger, F., Buonomo, S. B., Sfeir, A., and De Lange, T. (2013). 53BP1 regulates DSB repair using Rif1 to control 5' end resection. *Science* 339, 700–704.
- Zwet, M., Overkamp, W. J. I., Van Lange, R. E. E., Essers, J., Van Duijn-Goedhart, A., Wiggers, I., et al. (2002). Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. *Mol. Cell. Biol.* 22, 669–679.
- Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- Received: 30 January 2013; paper pending published: 11 March 2013; accepted: 24 April 2013; published online: 10 May 2013.
- Citation: Mladenov E, Magin S, Soni A and Iliakis G (2013) DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. *Front. Oncol.* 3:113. doi: 10.3389/fonc.2013.00113
- This article was submitted to *Frontiers in Radiation Oncology*, a specialty of *Frontiers in Oncology*.
- Copyright © 2013 Mladenov, Magin, Soni and Iliakis. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.

APPENDIX

Table A1 | Used abbreviations.

53BP1	p53 binding protein 1
5-FU	5-fluorouracil
ATM	Ataxia telangiectasia mutated
ATR	ATM and Rad3 related
BARD1	BRCA1-associated RING domain 1 protein
BIR	Break induced replication
BLM	Bloom's syndrome helicase
B-NHEJ	Backup non-homologous end-joining
BRCA1	Breast cancer susceptibility gene 1
BRCA2	Breast cancer susceptibility gene 2
CDKs	Cyclin dependent kinases
CHK1/2	Checkpoint kinase 1/2
CK2	Casein kinase 2
CML	Chronic myelogenous leukemia
CtIP	C-terminal binding protein 1 interacting protein
DDR	DNA damage response
dHJ	Double Holliday junction
D-loop	Displacement loop
DNA-PKcs	DNA dependent protein kinase catalytic subunit
D-NHEJ	DNA-PKcs dependent non-homologous end-joining
DSBs	Double-strand breaks
EXO1	Exonuclease 1
FEN1	Flap endonuclease 1
HDAC	Histone deacetylases
HRR	Homologous recombination repair
HU	Hydroxyurea
IR	Ionizing radiation
LIG1	DNA ligase 1
LIG3	DNA ligase 3
LIG4	DNA ligase 4
LOH	Loss of heterozygosity
MAPK	Mitogen activated protein kinases
MRE11	Meiotic recombination 11
MRN	MRE11/RAD50/NBS1
NBS1	Nijmegen breakage syndrome 1
NHEJ	Non-homologous end-joining
PARI	PCNA-associated recombination inhibitor
PARP-1	Poly (ADP-ribose) polymerase 1
PCNA	Proliferation cell nuclear antigen
PFGE	Pulse-field gel electrophoresis
PI3K	Phosphatidyl inositol 3-OH kinases
PLK1	Polo like kinase 1
PNK	Polynucleotide kinase phosphatase
PTMs	Post-translational modifications
RPA	Replication protein A
RTEL1	Regulator of telomere elongation helicase 1
SDSA	Synthesis-dependent strand annealing
SSA	Single-strand annealing
SSBs	Single-strand breaks
ssDNA	Single-stranded DNA
SUMO	Small ubiquitin like modifiers
WRN	Werner syndrome helicase
XLF	XRCC4 like factor
XRCC1	X-ray cross complemented 1
XRCC4	X-ray cross complemented 4